Sponsored by VMG Health | info@vmghealth.com | 214.369.4888

MD Anderson, Deerfield Management form joint venture to develop targeted cancer treatment

Houston-based The University of Texas MD Anderson Cancer Center and Deerfield Management have formed a joint venture company dedicated to performing drug discovery and research focused on advancing autophagy-targeted therapeutics for cancer treatment.

The joint venture, Vescor, will develop molecule inhibitors of a number of protein targets at critical nodes of the autophagy development. Autophagy plays an important role during the development and maintenance of cancerous tumors, allowing the tumors to obtain nutrients for growth and survival.

Core research and development activities will take place at MD Anderson's Institute for Applied Cancer Science.

The financial terms of the transaction, if any, have not been disclosed.

"Our goal is to drive novel drug discovery paradigms and develop cancer therapeutics targeting unexplored mechanisms that might provide high clinical impact. We are delighted to partner in this effort to advance novel drugs towards the clinic," said Phil Jones, PhD, executive director of IACS.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars